Five Insights Changing Alzheimer’s Care in 2025

Today, an estimated 57 million people are living with dementia, and around 60–70% of them have Alzheimer’s disease, the most common and devastating form of cognitive decline.

In the U.S., Alzheimer’s has climbed to the sixth leading cause of death, surpassing breast and prostate cancers combined. And the challenge is only growing: by 2050, the number of people affected is expected to triple to 150 million.

Yet amid these daunting numbers, something has shifted. The narrative around Alzheimer’s is no longer one of inevitability and despair, but of innovation, resilience, and rediscovery. From AI that predicts cognitive decline years in advance, to drugs that slow memory loss, the field is transforming faster than ever before.

The Alzheimer’s story today is less about “nothing can be done” and more about “what can we now do and how broadly can we deliver it?”

1. Blood Tests for Alzheimer’s Become a Reality

Until recently, diagnosing Alzheimer’s meant costly brain scans or invasive spinal taps. Now, a simple blood test can detect amyloid plaques — the key marker of the disease — with over 90% accuracy. Recently approved by the U.S. FDA, this test offers a faster, less invasive way to confirm early Alzheimer’s, helping doctors act before major symptoms appear.

In the UK, scientists at the University of Bath have also created a three-minute at-home memory test called Fastball, using EEG brainwave tracking to spot early cognitive decline.

Together, these innovations are turning Alzheimer’s detection from something complex and painful into something quick, simple, and personal.

2. A New Wave of Alzheimer’s Research

Last year brought the first real breakthroughs in treating Alzheimer’s disease. Two antibody-based drugs, lecanemab and donanemab, target the buildup of amyloid plaques in the brain and have been shown to slow cognitive decline by around 30%, and by as much as 60% if started early.

Results, however, remain mixed: one UK trial found only a modest 0.45-point improvement on an 18-point cognitive scale, while the costs of $27,000 to $34,000 a year put treatment beyond reach for many. The UK’s National Health Service has so far declined to make the drugs widely available.

Even so, their approval marks a historic shift — it is the first time medicine can alter, not just manage, the underlying biology of Alzheimer’s.

And the momentum is growing. The 2025 Alzheimer’s Drug Development Pipeline Report highlights 182 clinical trials testing 138 new therapies, the largest number in history. Nearly 40% of these focus on non-amyloid pathways such as neuroinflammation, mitochondrial dysfunction, and synaptic repair. Among them, 28 drugs are already in Phase 3, some showing early cognitive benefits.

For the first time, the field is moving beyond a single hypothesis toward a multi-pathway approach, one that combines immune regulation, neuroprotection, and early intervention to truly change the course of the disease.

3. The Herpes Connection — A Hidden Viral Link

Could a common cold sore virus hold clues to Alzheimer’s? Recent studies suggest that herpes simplex virus type 1 (HSV-1), the same virus responsible for cold sores, may play a role in triggering Alzheimer’s-related changes in the brain.

HSV-1 can remain dormant in nerve cells for decades. When reactivated, it may spark inflammation and the formation of amyloid plaques, one of the key hallmarks of Alzheimer’s. A large population study of over 340,000 older adults found that people with a history of HSV-1 infection had an 80% higher risk of developing Alzheimer’s, while those treated with antiviral medications had a 17% lower risk.

While causality remains under investigation, scientists see this as a potential paradigm shift, suggesting that infections and immune responses may play a larger role in neurodegeneration than previously thought. If the link is confirmed, it could open the door to entirely new prevention strategies, such as early antiviral treatment or even vaccines to reduce dementia risk.

In short, this line of research reframes Alzheimer’s not only as a disease of aging neurons, but as one potentially influenced by how the brain responds to hidden infections over time.

4. AI and the Future of Early Prediction

Artificial intelligence is giving doctors a head start against Alzheimer’s. Recent research shows AI models can accurately predict the presence of Alzheimer’s-hallmark proteins and forecast disease progression years before symptoms emerge. For example, a study from Boston University involving 12 185 participants from seven international cohorts developed an AI tool to predict amyloid and tau deposition using routine scans and health records.

Another 2025 framework from University of Cambridge  used AI to match therapies to patients based on how quickly their disease progressed — one subgroup experienced a 46% slower decline when matched with a drug based on AI-guided classification.

5. Rewiring the Brain: The Promise of Neural Implants

The next frontier in Alzheimer’s care may come from the lab bench, not the pharmacy. InBrain Neuroelectronics, a 2025 World Economic Forum Technology Pioneer, has developed ultra-thin graphene implants that can read and stimulate brain signals with remarkable precision,  a step toward restoring disrupted memory circuits.

At the University of California San Diego, a $5 million grant is advancing next-generation graphene electrodes to monitor brain activity and enable personalized neuro-modulation.

From Discovery to Dignity: The Road Ahead

The insights emerging in 2025 reveal not a single cure, but a changing mindset, one that sees Alzheimer’s not as an inevitable decline, but as a complex condition that can be understood, managed, and lived with differently. Science is moving from isolation to integration: connecting biology with behavior, molecules with memories, technology with care.

The challenge now is to bring these advances out of research papers and into real lives, making innovation accessible, care more personal, and dignity a constant companion on the long journey of Alzheimer’s.

At Cromos Pharma, we are proud to contribute to this transformation by supporting innovative clinical research and advancing studies that bring promising therapies closer to the patients who need them most.